Omnipaque
OMNIPAQUE™ (iohexol) Injection 300 350
Approved
Approval ID
3fa9bff0-676b-45d9-9d77-a6363c63395f
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Apr 25, 2023
Manufacturers
FDA
GE Healthcare Inc.
DUNS: 053046579
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
Iohexol
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0407-1414
Application NumberNDA020608
Product Classification
M
Marketing Category
C73594
G
Generic Name
Iohexol
Product Specifications
Route of AdministrationINTRAVENOUS, INTRAVASCULAR, ORAL, RECTAL
Effective DateApril 25, 2023
FDA Product Classification
INGREDIENTS (4)
TROMETHAMINEInactive
Code: 023C2WHX2V
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
IOHEXOLActive
Quantity: 350 mg in 1 mL
Code: 4419T9MX03
Classification: ACTIR
Iohexol
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0407-1413
Application NumberNDA020608
Product Classification
M
Marketing Category
C73594
G
Generic Name
Iohexol
Product Specifications
Route of AdministrationINTRAVENOUS, INTRAVASCULAR, INTRATHECAL, ORAL, RECTAL
Effective DateApril 25, 2023
FDA Product Classification
INGREDIENTS (4)
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
TROMETHAMINEInactive
Code: 023C2WHX2V
Classification: IACT
EDETATE CALCIUM DISODIUMInactive
Code: 25IH6R4SGF
Classification: IACT
IOHEXOLActive
Quantity: 300 mg in 1 mL
Code: 4419T9MX03
Classification: ACTIR